Skip to main content

Test Price

1,100 AED

โœ… Home Collection Available

JAK2 Mutation Detection (RNA) Qualitative Test in UAE | 1100 AED | DHA Licensed Laboratory

Executive Summary & Core Metrics

โœ“ Accuracy

99.9% diagnostic sensitivity via ISO 9001:2015 accredited real-time PCR.

โœ“ Logistics

VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM โ€“ 11 PM).

โœ“ Clinical Guidance

Telephonic post-test interpretation with a haematology specialist.

โœ“ Insurance

Direct billing verification via WhatsApp: +971545488731

Summary: High-sensitivity RNA-based qualitative test for the JAK2 V617F somatic mutation, essential for diagnosing Philadelphia-negative myeloproliferative neoplasms (MPNs) such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Performed on peripheral whole blood with confirmatory sequencing when indicated, fully compliant with DHA guidelines and federal data protection laws.

Test Overview & Methodology

The JAK2 Mutation Detection (RNA) Qualitative Test uses real-time quantitative PCR (RT-qPCR) to identify the c.1849G>T (V617F) mutation in the Janus kinase 2 gene transcript. This mutation is present in approximately 95% of polycythemia vera cases and 50โ€“70% of essential thrombocythemia and primary myelofibrosis cases. RNA extraction from peripheral whole blood ensures high sensitivity for detecting low-allele-burden clones, with confirmatory Sanger sequencing performed if the clinical suspicion remains high despite a negative result.

Feature DNA Labs UAE Test Standard Laboratory Alternative
Precision Real-Time PCR + Confirmatory Sanger Sequencing Conventional DNA PCR only
Methodology RNA-based qPCR (LC-MS/MS validated) DNA-based PCR, lower sensitivity for low VAF
Turnaround Time 24 h (phone) / 36 h (email) โ€“ 3rd working day report 5โ€“7 working days
Price 1,100 AED 850โ€“1,200 AED (range)

*Confirmatory sequencing performed when variant allele frequency is borderline or clinical indication persists.

Physician Insight & Safety Protocols

โ€œDetection of the JAK2 V617F mutation provides a definitive clonal marker for myeloproliferative neoplasms. However, a negative result does not rule out the disease, especially in young patients or those with atypical presentations. I always correlate molecular findings with bone marrow histology and dynamic blood counts before starting targeted therapy.โ€

โ€” Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403

Advisory: Medication Continuation

Do not stop or adjust any prescribed anticoagulants, antiplatelet agents, hydroxyurea, interferon, or JAK inhibitors without explicit instructions from your haematologist. This genetic test is for diagnostic confirmation only and does not replace emergency evaluation if you experience acute symptoms.

Red Flags & Exclusion Criteria

  • Active deep vein thrombosis, pulmonary embolism, or arterial thrombosis โ€“ seek emergency care before elective venipuncture.
  • Severe thrombocytopenia (platelet count <20 ร— 10โน/L) or active bleeding โ€“ risk of haemorrhage.
  • New onset of focal neurological deficits, vision loss, or severe headache โ€“ requires immediate ER evaluation.
  • Asymptomatic minors without prior haematology consultation should not be tested.

If you experience chest pain, sudden dyspnoea, or uncontrolled bleeding, call 998 or go to the nearest emergency department.

Patient FAQ & Clinical Guidance

1. What is the JAK2 mutation test used for?

It confirms the presence of the JAK2 V617F somatic mutation that drives myeloproliferative neoplasms (MPNs). This helps differentiate primary polycythaemia, essential thrombocythaemia, and myelofibrosis from secondary causes, guiding treatment decisions such as the use of JAK inhibitors. A positive result is diagnostic for clonal MPN, while a negative result may require further testing for CALR or MPL mutations.

2. Do I need to fast or stop medications before the blood draw?

No special preparation is needed. You may eat and drink normally and continue your prescribed medications. The sample is a simple peripheral whole blood draw (5โ€“10 mL) collected into an RNA-stabilising tube. Inform the phlebotomist if you are on anticoagulants; they do not interfere with the PCR but are important for clinical correlation.

3. How long does it take to get the result?

Preliminary result by phone in 24 hours; full written report within 3 working days. The test uses real-time PCR with confirmatory sequencing when necessary. Turnaround time is expedited compared to standard laboratories (5โ€“7 days). You will receive a detailed interpretation from our clinical genetics team, and we offer a telephonic post-test consultation to explain findings.

UAE Regulatory & Data Privacy Adherence

Data Protection & Legal Framework

All genetic test results are handled in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow the provisions of Federal Decree-Law No. 4 of 2016 on Medical Liability.

  • Your genetic information is encrypted and stored in DHA-compliant servers within the UAE.
  • Results are shared only with you and your designated physician.
  • Consent is obtained in writing before sample collection.
  • No data is transferred outside the UAE without explicit authorisation.

For any privacy-related queries, contact our Data Protection Officer at dpo@dnalabsuae.com.

Clinical & Logistical Metadata

Test Name JAK2 Mutation Detection (RNA) Qualitative Test
Price (AED) 1,100 AED
Turnaround Time 24 h (phone) / 36 h (email) โ€“ 3rd working day report
Sample Type / Matrix Peripheral whole blood (RNA-stabilising tube); VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM โ€“ 11 PM daily)
Methodology Used Real-Time PCR (qPCR) with confirmatory Sanger sequencing
ICD-10-CM Code D47.1 (Chronic myeloproliferative disease)
LOINC Code 36882-3 (JAK2 gene mutation identified in Blood by Molecular genetics method)
DHA Facility License & Address License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE

ุฏุนู… ุซู†ุงุฆูŠ ุงู„ู„ุบุฉ ู…ุชุงุญ

ุงู„ุชุญู‚ู‚ ู…ู† ุงู„ุชุบุทูŠุฉ ุงู„ุชุฃู…ูŠู†ูŠุฉ

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

ุชูˆู‚ู ุนู† ุงู„ุชุฎู…ูŠู†. ุฃุฑุณู„ ุตูˆุฑุฉ ู…ู† ุจุทุงู‚ุฉ ุงู„ุชุฃู…ูŠู† ูˆูˆุตูุฉ ุงู„ุทุจูŠุจ ุฅู„ู‰ ูุฑูŠู‚ ุงู„ุชุญู‚ู‚ ุงู„ู…ุนุชู…ุฏ ู…ู† ู‡ูŠุฆุฉ ุงู„ุตุญุฉ ุจุฏุจูŠ ุนุจุฑ ุงู„ูˆุงุชุณุงุจ. ุงุญุตู„ ุนู„ู‰ ุชุญุฏูŠุซ ุงู„ุญุงู„ุฉ ููŠ ุฏู‚ุงุฆู‚.

โœ… DHA Certified โœ… ISO 15189 โœ… HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

๐Ÿ…

ISMS 27001:2022

๐Ÿ“‹

ISO Accredited

๐Ÿ”’

HIPAA

All reports reviewed by DHA-Certified physicians